Press Releases

Press Releases

Search by keywords:

189 Press Releases found

Phase I Data Suggest PLX3397 Is a Potential Therapy for Patients with Advanced Pigmented Villonodular Synovitis

New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.

  • Wednesday, May 14, 2014

Paying It Forward: Breakthrough Prize Winners and Institutions Commit $3 Million in Support of Next Generation of Scientists

Three winners of the first-ever Breakthrough Prizes — Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center; Cornelia I. Bargmann, PhD, of the Rockefeller University; and Lewis C. Cantley, PhD, of Weill Cornell Medical College — have committed a portion of their Breakthrough Prize in Life Sciences award to establish a new annual prize for promising postdoctoral trainees.

  • Monday, May 12, 2014

Memorial Sloan Kettering Establishes New Center for Molecular Imaging and Nanotechnology

Memorial Sloan Kettering has launched a collaborative translational research center that will unite researchers specializing in two rapidly growing fields: molecular imaging and nanotechnology.

  • Friday, April 25, 2014

Study Reveals Mechanisms Cancer Cells Use to Establish Metastatic Brain Tumors

New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.

  • Thursday, February 27, 2014

Memorial Sloan Kettering Appoints Pereira & O’Dell New York as Creative Agency of Record, Media Storm as Media Agency of Record

Memorial Sloan Kettering announced the appointment of Pereira & O’Dell in New York as its creative agency of record and Media Storm as its media agency of record.

  • Tuesday, February 25, 2014

Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study

The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.

  • Wednesday, February 19, 2014

Research Links Obesity to Poor Survival in Tongue Cancer Patients

A collaborative effort among cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College has yielded an interesting association: Obesity prior to diagnosis is associated with a five-fold increase in the risk of death from early-stage squamous cell carcinoma of the tongue.

  • Tuesday, February 4, 2014

Newly Engineered Monoclonal Antibody Shows Promise, Moves toward Clinical Testing

Memorial Sloan Kettering and Eureka Therapeutics recently entered into a licensing agreement with Novartis to develop a unique monoclonal antibody.

  • Tuesday, January 28, 2014

Memorial Sloan Kettering Cancer Center Shares $540 Million in New Funding From Ludwig Cancer Research

Memorial Sloan Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research.

  • Monday, January 6, 2014

Foundation Medicine Launches FoundationOne™ Heme, Developed in Collaboration with Memorial Sloan Kettering Cancer Center

FoundationOne Heme was developed using technology, methods and computational algorithms developed by Foundation Medicine, combined with Memorial Sloan Kettering’s deep and vast expertise in clinical and laboratory research into hematologic malignancies.

  • Saturday, December 7, 2013